In another set of experiments, HD cell lines were incubated with soluble AC10 or HeFi-1 that were cross-linked in solution by the addition of soluble goat anti-mouse IgG antibodies. Under these cross-linking conditions, all four HD cell lines, when plated at $5x10^4$ cell/well, were growth inhibited by AC10 and HeFi-1 (FIG. 3). When the cells were plated at $5x10^3$ cell/well, all four HD cell lines were growth inhibited by AC10, while three of the four cell lines, HDLM-2, L540, and L428, were growth inhibited by HeFi-1 (FIG. 4).

B1

IN THE CLAIMS:

Please amend the claims as follows:

Replace claim 1 with the following amended claim:

1. (Amended) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) an antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein said antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent, respectively, and in the absence of cells other than cells of said Hodgkin's Disease cell line; and (b) a pharmaceutically acceptable carrier.

B2

REMARKS

Claims 1-8, 11 and 13-19 are under consideration. Claim 1 has been amended to more particularly point out and distinctly claim that which Applicants regard as the invention. In particular, claim 1 has been amended to indicate that the claim is directed to the treatment of Hodgkin's Disease by administering to a subject an antibody that exerts a cytostatic or cytotoxic effect on Hodgkin's Disease cells in the absence of other cell types. Support for the foregoing amendment can be found in the specification, *inter alia* in Section 5.3 at pages 23-25 and in Section 6 at page 50, in particular at lines 20-25. The specification has been amended to correct a typographical error. No new matter is added.